1
|
Mandrola J, Althouse AD, Foy A, Bhatt DL. Adaptive Trials in Cardiology: Some Considerations and Examples. Can J Cardiol 2021; 37:1428-1437. [PMID: 34252567 DOI: 10.1016/j.cjca.2021.06.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/29/2021] [Accepted: 06/29/2021] [Indexed: 12/15/2022] Open
Abstract
Adaptive trials hold great promise to enhance the evidence base supporting medical interventions. In this review, we will describe the basic principles of an adaptive trial and the different types of adaptive trials, show examples of adaptive trials, and conclude with the advantages and challenges of different types of adaptive trials. While regulatory bodies have expressed a desire to see more adaptive trials, resistance in the community remains. We hope that this review helps to build greater acceptance of the concept of adaptive trial design.
Collapse
Affiliation(s)
- John Mandrola
- Baptist Health Louisville, Louisville, Kentucky, USA.
| | - Andrew D Althouse
- Center for Clinical Trials and Data Coordination, Division of General Internal Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Andrew Foy
- Penn State Heart and Vascular Institute, Penn State College of Medicine, Hershey, Pennsylvania, USA; Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania, USA
| | - Deepak L Bhatt
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
| |
Collapse
|
2
|
Lim J, Wang L, Best N, Liu J, Yuan J, Yong F, Zhang L, Walley R, Gosselin A, Roebling R, Viele K. Reducing Patient Burden in Clinical Trials Through the Use of Historical Controls: Appropriate Selection of Historical Data to Minimize Risk of Bias. Ther Innov Regul Sci 2019; 54:850-860. [PMID: 32557308 DOI: 10.1007/s43441-019-00014-4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2019] [Accepted: 10/23/2019] [Indexed: 10/25/2022]
Abstract
Historical data have been used to augment or replace control arms in some rare disease and pediatric clinical trials. With greater availability of historical data and new methodology such as dynamic borrowing, the inclusion of historical data in clinical trials is an increasingly appealing approach for larger disease areas as well, as this can result in increased power and precision and can minimize the burden on patients in clinical trials. However, sponsors must assess whether the potential biases incurred with this approach outweigh the benefits and discuss this trade-off with the regulatory agencies. This paper discusses important points for the appropriate selection of historical controls for inclusion in the analysis of primary and/or key secondary endpoint(s) in clinical trials. The general steps are as follows: (1) Assess whether a trial is a suitable candidate for this approach. (2) If it is, then carefully identify appropriate historical trials to minimize selection bias. (3) Refine the historical control set if appropriate, for example, by selecting subsets of studies or patients. Identification of trial settings that are amenable to historical borrowing and selection of appropriate historical data using the principles discussed in this paper has the potential to lead to more efficient estimation and decision making. Ultimately, this efficiency gain results in lower patient burden and gets effective drugs to patients more quickly.
Collapse
Affiliation(s)
- Jessica Lim
- Clinical Statistics, GSK, 1250 S. Collegeville Road, Collegeville, PA, 19426-0989, USA.
| | - Li Wang
- Data and Statistical Sciences, Abbvie, North Chicago, IL, USA
| | - Nicky Best
- Advanced Biostatistics and Data Analytics, GSK, Uxbridge, Middlesex, UK
| | - Jeen Liu
- Statistical Science and Programming, Allergan, Irvine, CA, USA
| | - Jiacheng Yuan
- Statistical Science and Programming, Allergan, Irvine, CA, USA
| | - Florence Yong
- Biostatistics, Worldwide Research & Development, Pfizer, Cambridge, MA, USA
| | - Lanju Zhang
- Data and Statistical Sciences, Abbvie, North Chicago, IL, USA
| | - Rosalind Walley
- Centre for Excellence in Statistical Innovation, UCB, Slough, UK
| | | | - Robert Roebling
- Global Clinical Development and Medical Affairs, UCB, Monheim, Germany
| | | |
Collapse
|